27.48
+0.92(+3.46%)
Currency In USD
| Previous Close | 26.56 |
| Open | 26.29 |
| Day High | 27.6 |
| Day Low | 25.4 |
| 52-Week High | 31.13 |
| 52-Week Low | 5.49 |
| Volume | 318,372 |
| Average Volume | 324,585 |
| Market Cap | 1.03B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 17.55 |
| Moving Average 200 Days | 13.34 |
| Change | 0.92 |
Oruka Therapeutics Announces $180 Million Private Placement
GlobeNewswire Inc.
Sep 17, 2025 5:02 AM GMT
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases,
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
GlobeNewswire Inc.
Sep 17, 2025 5:00 AM GMT
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorabl
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV in Septembe